Table 2B.
Univariate analyses of potential prognostic factors for progression-free survival (PFS).
| Factors | PFS at 1 year (%) | PFS at 2 years (%) | PFS at 5 years (%) | p - value |
|---|---|---|---|---|
| Age | ||||
| 65 – 74 years | 57 | 37 | 20 | |
| 75 – 84 years | 54 | 32 | 9 | |
| ≥ 85 years | 21 | – | – | 0.08 |
| Gender | ||||
| Female | 54 | 26 | 12 | |
| Male | 55 | 37 | 16 | 0.60 |
| ECOG score | ||||
| 0 - 1 | 58 | 35 | 17 | |
| 2 - 3 | 37 | 26 | 6 | 0.06 |
| Charlson Comorbidity Index | ||||
| ≤ 5 | 59 | 39 | 25 | |
| > 5 | 50 | 29 | 6 | 0.05 |
| Clinical tumor classification (cT) | ||||
| 1 | 67 | 67 | 25 | |
| 2 | 53 | 32 | 8 | |
| 3 | 53 | 34 | 16 | |
| 4 | 59 | 32 | 22 | 1.00 |
| Clinical lymph node classification (cN) | ||||
| Nodal negative (N0) | 50 | 31 | 14 | |
| Nodal positive (N+) | 56 | 35 | 16 | 0.50 |
| Tumor stage (AJCC) | ||||
| 1 - 2 | 46 | 27 | 12 | |
| 3 | 56 | 38 | 14 | |
| 4a | 61 | 34 | 26 | 0.50 |
| Localization of the primary tumor | ||||
| 0 - 18 cm distance from the incisors (cervical) | 52 | 34 | 15 | |
| 18 - 24 cm distance from the incisors (upper thoracic third) | 67 | 44 | 23 | |
| 24 - 32 cm distance from the incisors (middle thoracic third) | 54 | 30 | 9 | |
| 32 - 40 cm distance from the incisors (lower thoracic third) | 44 | 29 | 19 | 0.80 |
| Administration of full-dose RT | ||||
| yes | 55 | 35 | 17 | |
| no | 45 | 11 | – | 0.04 |
| Cumulative dose of RT (EQD2) | ||||
| ≤ 50 Gy | 55 | 35 | 18 | |
| > 50 Gy | 55 | 33 | 14 | 0.90 |
| Administration of non-modified, full-dose chemotherapy | ||||
| yes | 69 | 51 | 26 | |
| no | 40 | 19 | 8 | 0.47 |
| Treatment concept | ||||
| Neoadjuvant CRT followed by surgical resection | 71 | 55 | 36 | |
| Definitive RT/CRT | 49 | 27 | 8 | < 0.001 |
ECOG, Eastern Cooperative Oncology Group; AJCC, American Joint Committee on Cancer; RT, radiotherapy; EQD2, equivalent dose in 2 Gy fractions; CRT, chemoradiotherapy. Bold values, significant p-values.